No two patients’ B-cell lymphomas are exactly alike, and that means that a cure will not come from a one-treatment-fits-all approach. So, our Moon Shot team is also enhancing the immune response by engineering a patient’s own cancer fighting cells, called T cells, to be selectively toxic to B-cell lymphoma. This approach is called adoptive cellular therapy and is a unique technique available to our team through collaboration with the Adoptive Cell Therapy platform within the Moon Shots Program^®Thống kê lô gan. With this resource so close at hand, this technique is already being applied in Phase I/II trials to treat patients with aggressive subtypes of B-cell lymphoma.